New targeted therapy vs. standard chemo for double-expressor DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new combination of targeted drugs (zanubrutinib, chidamide, and rituximab) with or without standard chemotherapy (CHOP) versus the usual R-CHOP regimen for people with a specific type of aggressive DLBCL (double-expressor). The goal is to see if the new approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed double-expressor DLBCL (a type of lymphoma where your biopsy shows high levels of two proteins called MYC and BCL2).
- You should be between 18 and 65 years old.
- You must be able to perform daily activities with little help (ECOG score 0-2).
- You need to have at least one tumor that can be measured on a scan (like a lymph node or other area).
- Your heart, kidneys, liver, and blood counts must be working well enough, as checked by tests.
- You cannot have had prior lymphoma treatment, other recent cancers, or serious heart/bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
This trial tests a higher dose of the targeted drug rituximab combined with standard chemotherapy (R-CHOP) for men with newly diagnosed, advanced DLBCL. The goal is to see if this stronger dose works better than the usual dose for this type of lymphoma.
Hear when a new BTK Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.